JBM HEALTHCARE (02161): Samuel Tsam Kwong Yip will be appointed as the new CEO.
Genbiotech (02161) announced that Mr. Wong Yew Wai will resign as the company's CEO to pursue other career development opportunities, effective from April 30, 2026. The board further announced that Mr. Chan Kwong Yip, the executive director and chairman of the board, will be appointed as the new CEO, effective from April 30, 2026.
JBM HEALTHCARE (02161) announces that Mr. Wong Yew Wai will resign as the Chief Executive Officer of the company to pursue other career development opportunities, effective from April 30, 2026. The board further announces that Mr. Sam Koon Yip, an executive director and chairman of the board, will be appointed as the new Chief Executive Officer, effective from April 30, 2026.
Related Articles
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)
From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?
New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)
From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?
New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
RECOMMEND
Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026
Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026
2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026
